Consolidated Basic Cancer Research Program

综合基础癌症研究计划

• 批准号: 10244063
• 负责人: Dario C Altieri
• 金额: $ 10万
• 依托单位: WISTAR INSTITUTE
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-04-01 至 2024-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10244063
• 关键词: Achievement; Agreement; Area; Award; Basic Cancer Research; Basic Science; Budgets; Cancer Center; Cancer Center Support Grant; Cancer Patient; Cancer Research Project; Cancer Vaccines; Chromatin; Clinic; Collaborations; Communities; Community Clinical Oncology Program; Competence; DNA Vaccines; Development; Direct Costs; Disease; Disease model; Drug resistance; Early Diagnosis; Education; Educational Activities; Ensure; Epigenetic Process; Faculty Recruitment; Family; Foundations; Foxes; Funding; Future; Goals; Grant; Immunology; Immunosuppression; Immunotherapy; Infrastructure; Institutes; Institution; Interdisciplinary Study; Investments; Leadership; Malignant Neoplasms; Malignant neoplasm of lung; Malignant neoplasm of ovary; Malignant neoplasm of pancreas; Mission; Neoplasm Metastasis; Oncogenic; Pathway interactions; Patients; Peer Review; Pilot Projects; Program Research Project Grants; Publications; Research; Research Personnel; Resource Sharing; Running; Science; Scientist; Site; Specialized Program of Research Excellence; Therapeutic; Therapeutic Intervention; Time; Training; Training and Education; Tumor Immunity; Untranslated RNA; Vaccines; Virus Inhibitors; Vision; Workforce Development; anticancer research; cancer research center director; checkpoint inhibition; collaborative approach; commercialization; design; drug discovery; early detection biomarkers; innovation; inter-institutional; melanoma; member; multidisciplinary; next generation; novel; novel therapeutics; patient oriented; programs; recruit; response; synergism; tool; translational cancer research; translational model; tumor; tumor immunology; tumor metabolism; tumorigenesis; vaccine immunotherapy

PROJECT SUMMARY – OVERALL The vision of the Wistar Cancer Center is to conquer cancer through outstanding research, education and partnership, and its mission is to merge basic, translational, and patient-oriented cancer research in a single scientific continuum. Rated Exceptional (Impact score, 19) at the 2013 renewal of the Cancer Center Support Grant (CCSG), the Cancer Center has continued on a path of scientific excellence, impactful contributions in basic and translational cancer research, and productive partnerships with neighboring academic Institutions. Leveraging the 2014 opening of the Fox Research Tower, the largest building built on Wistar campus, a science-focused leadership where the Cancer Center Director (Dr. Altieri) is also Institute President and Chief Executive Officer (CEO) and a nimble, opportunity-driven administration, the Cancer Center has recruited 10 new members during the last CCSG budget cycle, expanded technological capabilities in all Shared Resources, and realigned Programs for optimal scientific impact and collaboration. Its basic research contributions have elucidated fundamental underpinnings of tumorigenesis in chromatin organization, non-coding RNA, local immunosuppression and metastatic competence, whereas disease site-specific themes in melanoma and ovarian cancer have run the gamut from defining new oncogenic pathways to unraveling mechanisms of drug resistance to bringing novel therapeutics to the clinic. Against this backdrop, the Cancer Center currently receives $12.4 million in peer-reviewed, cancer-related funding, with $8.9 million from the NCI for an exceptional cancer focus of 76%. The three Programs in the Cancer Center have succeeded in a uniquely collaborative approach to cancer research: 76% of all peer-reviewed funding and over 40% of “discovery” publications in the Programs are currently the product of multi-investigator collaborations. For a Cancer Center with only 27 members, Wistar now contributes to three Specialized Programs of Research Excellence (SPOREs), five Program Project grants, six multi-PI awards, and four U-type grants. The overarching goal of the Cancer Center to move its basic discoveries to the clinic has been met with a landmark agreement with the Helen F. Graham Cancer Center (HFGCC), the first partnership in the nation to bring together two NCI-sponsored programs: an NCI-designated “basic” Cancer Center (Wistar) and a member of the NCI Community Oncology Research Program (HFGCC). This has enabled impactful collaborations between Wistar scientists and HFGCC clinicians, bringing cutting-edge cancer research to the community. The Cancer Center will continue on this successful trajectory of accomplishments during the next CCSG budget cycle, creating new, multidisciplinary research themes in basic and translational tumor immunology, early- stage academic drug discovery, and exploitation of tumor metabolism for novel cancer therapeutics. As an organization solely dedicated to biomedical discovery, Wistar is uniquely poised to continue making transformative advances in basic, translational, and patient-focused cancer research.

项目概要-总体 Wistar癌症中心的愿景是通过杰出的研究，教育和 它的使命是将基础、转化和以患者为导向的癌症研究融合在一个 单一的科学连续体。在2013年癌症中心的更新中被评为优秀（影响评分，19） 支持补助金（CCSG），癌症中心继续在科学卓越的道路上， 在基础和转化癌症研究方面的贡献，以及与邻国的富有成效的伙伴关系， 学术机构利用2014年福克斯研究塔（Fox Research Tower）的开放，福克斯研究塔是福克斯研究塔上建造的最大建筑 Wistar校园，一个以科学为中心的领导，癌症中心主任（博士Altieri）也是研究所 总裁兼首席执行官（CEO）和灵活，机会驱动的管理，癌症 中心在上一个CCSG预算周期内招募了10名新成员，扩大了技术能力 在所有共享资源，并重新调整计划，以实现最佳的科学影响和合作。其基本 研究成果已经阐明了染色质组织中肿瘤发生的基本基础， 非编码RNA，局部免疫抑制和转移能力，而疾病部位特异性主题 在黑色素瘤和卵巢癌中的研究已经从定义新的致癌途径到解开 耐药性机制，为临床带来新的治疗方法。在这种背景下，巨蟹座 该中心目前获得了1240万美元的同行评审，癌症相关资金，其中890万美元来自NCI 76%的癌症病灶。癌症中心的三个项目成功地 独特的癌症研究合作方法：76%的同行评审资金和超过40%的 该计划中的“发现”出版物目前是多研究者合作的产物。用于 癌症中心只有27名成员，Wistar现在为三个专业研究项目做出贡献 卓越奖（SPORE），五个计划项目赠款，六个多PI奖和四个U型赠款。的 癌症中心将其基本发现转移到临床的总体目标已经达到了一个里程碑 与Helen F.格雷厄姆癌症中心（HFGCC），在全国第一个合作伙伴关系， 两个国家癌症研究所赞助的计划：一个国家癌症研究所指定的“基本”癌症中心（Wistar）和一个国家癌症研究所的成员。 NCI社区肿瘤学研究计划（HFGCC）。这使得有影响力的合作成为可能 Wistar科学家和HFGCC临床医生之间的合作，为社区带来了尖端的癌症研究。的 在下一个CCSG预算期间，癌症中心将继续沿着这一成功的轨道取得成就 周期，创造新的，多学科的研究主题，在基础和转化肿瘤免疫学，早期- 阶段性学术药物发现和肿瘤代谢用于新癌症治疗的开发。作为 组织完全致力于生物医学发现，Wistar是独一无二的准备继续使 在基础、转化和以患者为中心的癌症研究方面取得了变革性进展。